Bio-Rad Laboratories has added multiple new assays to its precision oncology research portfolio, according to an announcement.

The new assays available for use with the QX700 ddPCR systems provide researchers with additional tools designed to support mutation detection research, liquid biopsy workflows, tumor-informed assay development, molecular residual disease (MRD) research, and multiplex biomarker analysis. 

The new offerings include:

• The QX700 ddPCR EGFR Exon 19 Deletions Screening Kit and QX700 ddPCR KRAS G12/G13 Screening Kit for use with the QX700 systems are intended to support research involving EGFR and KRAS mutations across multiple solid tumor research applications.
• Dark Probe Mutation Detection Assays to help advance translational research in oncology applications, especially for liquid biopsy mutation detection and monitoring in liquid, MRD, liquid biopsy and translational research workflows. Designed to replace the wild-type fluorescent probe in existing ddPCR workflows, quencher-only dark probes suppress wild-type background and free a detection channel allowing up to four mutation targets to be analyzed in a single well, increasing multiplexing capabilities and reducing demand for sample volume.
• Thirteen oncology focused ddPLEXCrystalTag ddPCR Assays and CrystalTag Reporters will be available soon. Bio-Rad’s CrystalTag technology separates target recognition from signal generation, enabling flexible assay design and multiplexed detection of up to 21 targets in a single reaction well on the QX700 platform, and supporting efficient development of custom research workflows. These new solutions, including assays for mutation detection of the ESR1 mutation, KRAS mutations, and HPV, enable high-plex ddPCR research across translational research, biomarker discovery, biopharmaceutical research, and advanced multiplex assay development.

*The ddPCR assays manufactured by Bio-Rad Laboratories are for Research Use Only (RUO) and are not intended for use in diagnostic procedures. Any clinical use or clinical claims made by customers or researchers are subject to their own in-house validation and must comply with applicable local regulations.

Visit Bio-Rad for more information